In a first-in-human, phase 1 study utilizing dual-targeting CAR T cells (EGFR-IL13Rα2 CAR-T cells) in patients with recurrent GBM, they showed early effectiveness signs. The gene discussed is IL13RA2; the disease is glioblastoma.